UNDERSTANDING NEURODEGENERATIVE DISEASE PATHOLOGY: A GUIDE FOR GENERAL NEUROLOGISTS
Article Sidebar
Main Article Content
Аннотация:
Neurodegeneration involves the progressive dysfunction or loss of selectively vulnerable neurons in the brain and spinal cord. Despite significant advancements in fluid and imaging biomarkers, the definitive diagnosis of most neurodegenerative diseases still depends on neuropathological examination. Careful clinicopathological correlation has been instrumental in shaping clinical diagnostic criteria, enhancing our understanding of disease progression, and uncovering conditions with substantial public health relevance, such as variant Creutzfeldt-Jakob disease, iatrogenic amyloid-β deposition, and chronic traumatic encephalopathy. Neuropathological analysis can also reveal previously undetected genetic conditions with potential implications for family members. Additionally, detailed postmortem tissue examination plays a vital role in research aimed at uncovering molecular mechanisms of neurodegeneration and developing or validating biomarkers. This review highlights the hallmark pathological features of neurodegenerative diseases commonly encountered in general neurology, including Alzheimer’s disease and Parkinson’s disease; rarer but recognized disorders like progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy; as well as emerging entities such as chronic traumatic encephalopathy and age-related tau astrogliopathy.
Article Details
Как цитировать:
Библиографические ссылки:
Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 2014;15:384–96. doi:10.1038/nrm3810
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18:101–13. doi:10.1038/nrn.2016.178
Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol 2021;20:222–34. doi:10.1016/S1474-4422(20)30440-3
Sirkis DW, Bonham LW, Johnson TP, et al. Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol Psychiatry 2022;27. doi:10.1038/s41380-022-01531-9
Jaunmuktane Z, Mead S, Ellis M, et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 2015;526:247–50. doi:10.1038/nature15704
Musayeva, S. I. (2024). ADVANTAGES AND DISADVANTAGES OF INTERACTIVE METHODS INTRODUCING THE СLT (СOMMUNIСATIVE LANGUAGE TEACHING) APPROACH. World Scientific Research Journal, 32(1), 217-219.
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 2019;14:32. doi:10.1186/s13024-019-0333-5
Hardy J, Duff K, Hardy KG, et al. Genetic dissection of Alzheimer’s disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1998;1:355–8. doi:10.1038/1565
Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008;63:204–12. doi:10.1002/ana.21223
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59. doi:10.1007/BF00308809
Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012;8:1–13. doi:10.1016/j.jalz.2011.10.007